Changes in Three-Dimensional Volumetric Liver Fat Fraction after Cure of Chronic Hepatitis C Infection with Direct-Acting Antivirals
Open Access
- 14 January 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Abstract
Background: It remains unclear if cure of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) leads to change in liver fat fraction and if this change differs from people without HCV observed over similar time. We evaluated the change in three-dimensional volumetric liver fat fraction by magnetic resonance imaging (MRI) prior to DAA treatment and 18 months following initiation and compared changes in uninfected controls over 18 months. Methods: We conducted a cohort study of 35 participants who initiated DAAs and achieved cure and 42 without HCV infection as controls. At enrollment and 18 months later, participants had measurements of height, body weight, and three-dimensional volumetric liver fat fraction and cross-sectional area of abdominal subcutaneous and visceral adipose tissue by MRI. Multivariable linear regression was used to estimate group differences in mean changes in liver fat fraction. Results: Mean change in three-dimensional volumetric liver fat fraction between Months 0 and 18 was +2.89% (95% CI: + 0.89%, + 4.88%) among participants with cured HCV and +0.48% (95% CI: -1.02%, + 1.97%) among controls (between group difference p-value=0.05). After adjustment for age, sex, smoking, and change in body mass index, the mean difference in liver fat fraction change between Months 0 and 18 was +3.11% (95% CI: + 0.46%, + 5.76%; p = 0.022) higher for participants with HCV versus controls. Conclusions: Three-dimensional volumetric liver fat fraction by MRI significantly increased between Months 0 and 18 following successful treatment of HCV infection, but this finding was not observed from Month 0 to 18 among participants without HCV infection.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01 AI136626)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08 DK132977)
- National Center for Advancing Translational Sciences (UL1 TR001878)
- National Institutes of Health
This publication has 27 references indexed in Scilit:
- Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antiviralsClinics and Research in Hepatology and Gastroenterology, 2025
- Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting AntiviralsJournal of General Internal Medicine, 2020
- Diurnal Variation of Proton Density Fat Fraction in the Liver Using Quantitative Chemical Shift Encoded MRIJournal of Magnetic Resonance Imaging, 2019
- MR-based assessment of body fat distribution and characteristicsEuropean Journal of Radiology, 2016
- Fatty liver deposition and sparing: a pictorial reviewInsights into Imaging, 2011
- Human immunodeficiency virus (HIV)‐1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein‐1 expressionHepatology, 2010
- Liver biopsy†Hepatology, 2009
- Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3Journal of Hepatology, 2000
- Screening with the alcohol use disorders identification test (AUDIT) in an inner-city populationJournal of General Internal Medicine, 1994
- The drug abuse screening testAddictive Behaviors, 1982